Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Osteosarcoma Epidemiology Forecast

DelveInsight’s ‘Osteosarcoma - Epidemiology Forecast–2030’ report delivers an in-depth understanding of the Osteosarcoma, historical and forecasted epidemiology as well as the Osteosarcoma trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Osteosarcoma Disease Understanding

Osteosarcoma (osteogenic sarcoma) is the most common type of bone cancer that usually develops in the osteoblast cells of the bone. It mostly occurs in the long bones around the knee. Other sites include the upper leg, or thighbone, the lower leg, upper arm bone, or any bone in the body, including those in the pelvis, shoulder, and skull. It may spread to nearby tissues, such as tendons or muscles, and may also metastasize through the bloodstream to other organs or bones in the body.


It can be classified as primary or secondary based on the location and spread of cancer. When cancer starts in bone tissue, it is called primary bone cancer. Whereas, when cancer cells travel to the bone from elsewhere, it is called secondary or metastatic bone cancer. Furthermore, based on the histological features, it can be categorized into high-grade, intermediate-grade, and low-grade Osteosarcoma; each category has different subtypes.


Pain is the most common symptom of Osteosarcoma; this pain may come and go at first, but, gradually, it becomes constant. Some patients may have swelling or a mass in the area of the tumor. If the tumor is located in the leg, the patient may also develop a limp. Osteosarcoma weakens the bones, and patients may develop pathologic bone fractures in the area of the tumor.

Osteosarcoma Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of Osteosarcoma, Gender-specific Incident Cases of Osteosarcoma, Age-specific Incident Cases of Osteosarcoma, Stage-specific Incident Cases of Osteosarcoma, Sub-types specific Incident Cases of Osteosarcoma, and Site-specific Incident Cases of Osteosarcoma scenario of Osteosarcoma in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2018 to 2030.

Osteosarcoma Detailed Epidemiology Segmentation

  • As per DelveInsight estimates, the Incident cases of Osteosarcoma in the 7MM were 2,228 cases in 2020 during the study period (2018–2030).
  • The incident cases of Osteosarcoma in the United States was 1,174 patients in 2020.
  • Our Reports estimate that males have higher cases in comparison to females. In 2020, males and females accounted for 620 and 554 cases of Osteosarcoma.
  • Based on the stages of cancer, Osteosarcoma is categorized into localized, regional, and distant stages. Localized and regional are further defined as non-metastatic, whereas, the ‘distant’ stage is defined as metastasis. The localized and regional stage incident cases accounted for 387 and 563 cases in 2020. In the same year, distant staged Osteosarcoma cases contributed to 223 cases in the US.
  • Osteosarcoma is classified into various subtypes based on the histological findings. The most common subtypes based on the various published studies are conventional, telangiectatic, parosteal, periosteal, and other Osteosarcoma. In the US, Conventional osteosarcoma accounted for nearly 80% of total osteosarcoma cases. Remaining ~20% cases include telangiectatic, parosteal, periosteal, and other Osteosarcoma.
  • In the EU5, the highest Incident cases were reported to be in Germany followed by France and the United Kingdom whereas the lowest Incident cases were reported in Spain from 2018 through 2030.
  • Japan was reported to have 199 Incident cases in 2020.

Scope of the Report

  • The report covers the descriptive overview of Osteosarcoma, explaining its etiology, signs and symptoms, pathophysiology, and genetic basis.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Osteosarcoma.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Incident Cases of Osteosarcoma, Gender-specific Incident Cases of Osteosarcoma, Age-specific Incident Cases of Osteosarcoma, Stage-specific Incident Cases of Osteosarcoma, Sub-types specific Incident Cases of Osteosarcoma, and Site-specific Incident Cases of Osteosarcoma.

Report Highlights

  • 10-Year Forecast of Osteosarcoma
  • 7MM Coverage
  • Total Incident Cases of Osteosarcoma
  • Gender-specific Incident Cases of Osteosarcoma
  • Age-specific Incident Cases of Osteosarcoma
  • Stage-specific Incident Cases of Osteosarcoma
  • Sub-types specific Incident Cases of Osteosarcoma
  • Site-specific Incident Cases of Osteosarcoma

Key Questions Answered

  • What is the disease risk, burden and unmet needs of Osteosarcoma?
  • What is the historical Osteosarcoma patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Osteosarcoma at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Osteosarcoma?
  • Out of the above-mentioned countries, which country would have the highest incident population of Osteosarcoma during the forecast period (2021–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?

Reasons to buy

The Osteosarcoma report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM Osteosarcoma epidemiology forecast.
  • The Osteosarcoma epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Osteosarcoma epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Executive Summary of Osteosarcoma

3. Osteosarcoma Epidemiology Overview at a Glance

3.1. Epidemiology Share (%) distribution by Country of Osteosarcoma in 2018

3.2. Epidemiology Share (%) distribution by Country of Osteosarcoma in 2030

4. Disease Background and Overview: Osteosarcoma (OS)

4.1. Introduction

4.2. Classification of Osteosarcoma

4.3. Symptoms

4.4. Causes and risk factors

4.5. Pathogenesis of Osteosarcoma

4.6. Biomarkers

4.7. Diagnosis

4.7.1. Diagnostic Algorithm

4.7.2. Staging of Osteosarcoma

4.7.3. Diagnostic Guidelines

5. Epidemiology and Patient Population

5.1. Key Findings

5.2. Methodology

5.3. Total Incident Cases of Osteosarcoma in the 7MM

6. United States Epidemiology

6.1. Assumptions and Rationale

6.2. Total Incident Cases of Osteosarcoma in the United States

6.3. Gender-specific Incident Cases of Osteosarcoma in the United States

6.4. Age-specific Incident Cases of Osteosarcoma in the United States

6.5. Stage-specific Incident Cases of Osteosarcoma in the United States

6.6. Sub-types specific Incident Cases of Osteosarcoma in the United States

6.7. Site-specific Incident Cases of Osteosarcoma in the United States

7. EU5 Epidemiology

7.1. Germany Epidemiology

7.1.1. Assumptions and Rationale

7.1.2. Total Incident Cases of Osteosarcoma in Germany

7.1.3. Gender-specific Incident Cases of Osteosarcoma in Germany

7.1.4. Age-specific Incident Cases of Osteosarcoma in Germany

7.1.5. Stage-specific Incident Cases of Osteosarcoma in Germany

7.1.6. Sub-types specific Incident Cases of Osteosarcoma in Germany

7.1.7. Site-specific Incident Cases of Osteosarcoma in Germany

7.2. France Epidemiology

7.2.1. Assumptions and Rationale

7.2.2. Total Incident Cases of Osteosarcoma in France

7.2.3. Gender-specific Incident Cases of Osteosarcoma in France

7.2.4. Age-specific Incident Cases of Osteosarcoma in France

7.2.5. Stage-specific Incident Cases of Osteosarcoma in France

7.2.6. Sub-types specific Incident Cases of Osteosarcoma in France

7.2.7. Site-specific Incident Cases of Osteosarcoma in France

7.3. Italy Epidemiology

7.3.1. Assumptions and Rationale

7.3.2. Total Incident Cases of Osteosarcoma in Italy

7.3.3. Gender-specific Incident Cases of Osteosarcoma in Italy

7.3.4. Age-specific Incident Cases of Osteosarcoma in Italy

7.3.5. Stage-specific Incident Cases of Osteosarcoma in Italy

7.3.6. Sub-types specific Incident Cases of Osteosarcoma in Italy

7.3.7. Site-specific Incident Cases of Osteosarcoma in Italy

7.4. Spain Epidemiology

7.4.1. Assumptions and Rationale

7.4.2. Total Incident Cases of Osteosarcoma in Spain

7.4.3. Gender-specific Incident Cases of Osteosarcoma in Spain

7.4.4. Age-specific Incident Cases of Osteosarcoma in Spain

7.4.5. Stage-specific Incident Cases of Osteosarcoma in Spain

7.4.6. Sub-types specific Incident Cases of Osteosarcoma in Spain

7.4.7. Site-specific Incident Cases of Osteosarcoma in Spain

7.5. United Kingdom Epidemiology

7.5.1. Assumptions and Rationale

7.5.2. Total Incident Cases of Osteosarcoma in the United Kingdom

7.5.3. Gender-specific Incident Cases of Osteosarcoma in the United Kingdom

7.5.4. Age-specific Incident Cases of Osteosarcoma in the United Kingdom

7.5.5. Stage-specific Incident Cases of Osteosarcoma in the United Kingdom

7.5.6. Sub-types specific Incident Cases of Osteosarcoma in the United Kingdom

7.5.7. Site-specific Incident Cases of Osteosarcoma in the United Kingdom

8. Japan Epidemiology

8.1. Assumptions and Rationale

8.2. Total Incident Cases of Osteosarcoma in Japan

8.3. Gender-specific Incident Cases of Osteosarcoma in Japan

8.4. Age-specific Incident Cases of Osteosarcoma in Japan

8.5. Stage-specific Incident Cases of Osteosarcoma in Japan

8.6. Sub-types specific Incident Cases of Osteosarcoma in Japan

8.7. Site-specific Incident Cases of Osteosarcoma in Japan

9. Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

List of Tables

Table 1: Summary of Osteosarcoma, Epidemiology and Key Events (2018–2030)

Table 2: Enneking MSTS staging system

Table 3: AJCC staging system for bone sarcoma

Table 4: Total Incident Cases of Osteosarcoma in the 7MM (2018–2030)

Table 5: Total Incident Cases of Osteosarcoma in the US (2018–2030)

Table 6: Gender-specific Incident Cases of Osteosarcoma in the US (2018–2030)

Table 7: Age-specific Incident Cases of Osteosarcoma in the US (2018–2030)

Table 8: Stage-specific Incident Cases of Osteosarcoma in the US (2018–2030)

Table 9: Sub-types specific Incident Cases of Osteosarcoma in the US (2018–2030)

Table 10: Site-specific Incident Cases of Osteosarcoma in the US (2018–2030)

Table 11: Total Incident Cases of Osteosarcoma in Germany (2018–2030)

Table 12: Gender-specific Incident Cases of Osteosarcoma in Germany (2018–2030)

Table 13: Age-specific Incident Cases of Osteosarcoma in Germany (2018–2030)

Table 14: Stage-specific Incident Cases of Osteosarcoma in Germany (2018–2030)

Table 15: Sub-types specific Incident Cases of Osteosarcoma in Germany (2018–2030)

Table 16: Site-specific Incident Cases of Osteosarcoma in Germany (2018–2030)

Table 17: Total Incident Cases of Osteosarcoma in France (2018–2030)

Table 18: Gender-specific Incident Cases of Osteosarcoma in France (2018–2030)

Table 19: Age-specific Incident Cases of Osteosarcoma in France (2018–2030)

Table 20: Stage-specific Incident Cases of Osteosarcoma in France (2018–2030)

Table 21: Sub-types specific Incident Cases of Osteosarcoma in France (2018–2030)

Table 22: Site-specific Incident Cases of Osteosarcoma in France (2018–2030)

Table 23: Total Incident Cases of Osteosarcoma in Italy (2018–2030)

Table 24: Gender-specific Incident Cases of Osteosarcoma in Italy (2018–2030)

Table 25: Age-specific Incident Cases of Osteosarcoma in Italy (2018–2030)

Table 26: Stage-specific Incident Cases of Osteosarcoma in Italy (2018–2030)

Table 27: Sub-types specific Incident Cases of Osteosarcoma in Italy (2018–2030)

Table 28: Site-specific Incident Cases of Osteosarcoma in Italy (2018–2030)

Table 29: Total Incident Cases of Osteosarcoma in Spain (2018–2030)

Table 30: Gender-specific Incident Cases of Osteosarcoma in Spain (2018–2030)

Table 31: Age-specific Incident Cases of Osteosarcoma in Spain (2018–2030)

Table 32: Stage-specific Incident Cases of Osteosarcoma in Spain (2018–2030)

Table 33: Sub-types specific Incident Cases of Osteosarcoma in Spain (2018–2030)

Table 34: Site-specific Incident Cases of Osteosarcoma in Spain (2018–2030)

Table 35: Total Incident Cases of Osteosarcoma in the United Kingdom (2018–2030)

Table 36: Gender-specific Incident Cases of Osteosarcoma in the United Kingdom (2018–2030)

Table 37: Age-specific Incident Cases of Osteosarcoma in the United Kingdom (2018–2030)

Table 38: Stage-specific Incident Cases of Osteosarcoma in the United Kingdom (2018–2030)

Table 39: Sub-types specific Incident Cases of Osteosarcoma in the United Kingdom (2018–2030)

Table 40: Site-specific Incident Cases of Osteosarcoma in the United Kingdom (2018–2030)

Table 41: Total Incident Cases of Osteosarcoma in Japan (2018–2030)

Table 42: Gender-specific Incident Cases of Osteosarcoma in Japan (2018–2030)

Table 43: Age-specific Incident Cases of Osteosarcoma in Japan (2018–2030)

Table 44: Stage-specific Incident Cases of Osteosarcoma in Japan (2018–2030)

Table 45: Sub-types specific Incident Cases of Osteosarcoma in Japan (2018–2030)

Table 46: Site-specific Incident Cases of Osteosarcoma in Japan (2018–2030)

List of Figures

Figure 1: Biologic growth pattern of osteosarcomas

Figure 2: Symptoms of osteosarcoma

Figure 3: Risk factors of osteosarcoma

Figure 4: Epigenetic events which may contribute to the initiation and progression of OS

Figure 5: Participation of microRNAs (miRs) in OS development

Figure 6: Role of lncRNAs and circRNAs in osteosarcoma

Figure 7: General diagnostic strategy for bone sarcomas

Figure 8: Total Incident Cases of Osteosarcoma in the 7MM (2018–2030)

Figure 9: Total Incident cases of Osteosarcoma in the US (2018–2030)

Figure 10: Gender-specific Incident cases of Osteosarcoma in the US (2018–2030)

Figure 11: Age-specific Incident Cases of Osteosarcoma in the US (2018–2030)

Figure 12: Stage-specific Incident Cases of Osteosarcoma in the US (2018–2030)

Figure 13: Sub-types specific Incident Cases of Osteosarcoma in the US (2018–2030)

Figure 14: Site-specific Incident Cases of Osteosarcoma in the US (2018–2030)

Figure 15: Total Incident cases of Osteosarcoma in Germany (2018–2030)

Figure 16: Gender-specific Incident cases of Osteosarcoma in Germany (2018–2030)

Figure 17: Age-specific Incident Cases of Osteosarcoma in Germany (2018–2030)

Figure 18: Stage-specific Incident Cases of Osteosarcoma in Germany (2018–2030)

Figure 19: Sub-types specific Incident Cases of Osteosarcoma in Germany (2018–2030)

Figure 20: Site-specific Incident Cases of Osteosarcoma in Germany (2018–2030)

Figure 21: Total Incident cases of Osteosarcoma in France (2018–2030)

Figure 22: Gender-specific Incident cases of Osteosarcoma in France (2018–2030)

Figure 23: Age-specific Incident Cases of Osteosarcoma in France (2018–2030)

Figure 24: Stage-specific Incident Cases of Osteosarcoma in France (2018–2030)

Figure 25: Sub-types specific Incident Cases of Osteosarcoma in France (2018–2030)

Figure 26: Site-specific Incident Cases of Osteosarcoma in France (2018–2030)

Figure 27: Total Incident cases of Osteosarcoma in Italy (2018–2030)

Figure 28: Gender-specific Incident cases of Osteosarcoma in Italy (2018–2030)

Figure 29: Age-specific Incident Cases of Osteosarcoma in Italy (2018–2030)

Figure 30: Stage-specific Incident Cases of Osteosarcoma in Italy (2018–2030)

Figure 31: Sub-types specific Incident Cases of Osteosarcoma in Italy (2018–2030)

Figure 32: Site-specific Incident Cases of Osteosarcoma in Italy (2018–2030)

Figure 33: Total Incident cases of Osteosarcoma in Spain (2018–2030)

Figure 34: Gender-specific Incident cases of Osteosarcoma in Spain (2018–2030)

Figure 35: Age-specific Incident Cases of Osteosarcoma in Spain (2018–2030)

Figure 36: Stage-specific Incident Cases of Osteosarcoma in Spain (2018–2030)

Figure 37: Sub-types specific Incident Cases of Osteosarcoma in Spain (2018–2030)

Figure 38: Site-specific Incident Cases of Osteosarcoma in Spain (2018–2030)

Figure 39: Total Incident cases of Osteosarcoma in the United Kingdom (2018–2030)

Figure 40: Gender-specific Incident cases of Osteosarcoma in the United Kingdom (2018–2030)

Figure 41: Age-specific Incident Cases of Osteosarcoma in the United Kingdom (2018–2030)

Figure 42: Stage-specific Incident Cases of Osteosarcoma in the United Kingdom (2018–2030)

Figure 43: Sub-types specific Incident Cases of Osteosarcoma in the United Kingdom (2018–2030)

Figure 44: Site-specific Incident Cases of Osteosarcoma in the United Kingdom (2018–2030)

Figure 45: Total Incident cases of Osteosarcoma in Japan (2018–2030)

Figure 46: Gender-specific Incident cases of Osteosarcoma in Japan (2018–2030)

Figure 47: Age-specific Incident Cases of Osteosarcoma in Japan (2018–2030)

Figure 48: Stage-specific Incident Cases of Osteosarcoma in Japan (2018–2030)

Figure 49: Sub-types specific Incident Cases of Osteosarcoma in Japan (2018–2030)

Figure 50: Site-specific Incident Cases of Osteosarcoma in Japan (2018–2030)

Forward to Friend

Need A Quote